Stephen R Marder, Stine R Meehan, Catherine Weiss, Dalei Chen, Mary Hobart, Nanco Hefting
{"title":"Brexpiprazole对精神分裂症患者跨症状域的影响:短期和长期研究的事后分析","authors":"Stephen R Marder, Stine R Meehan, Catherine Weiss, Dalei Chen, Mary Hobart, Nanco Hefting","doi":"10.1093/schizbullopen/sgab014","DOIUrl":null,"url":null,"abstract":"<p><p>The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this <i>post hoc</i> analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) 'Marder factors.' Data were included from three 6-week, randomized, double-blind, placebo-controlled studies; a 52-week, randomized, double-blind, placebo-controlled maintenance treatment study; and two 52-week open-label extension (OLEx) studies-all in schizophrenia (DSM-IV-TR criteria). Patients receiving oral brexpiprazole were dosed at 2-4 mg/day (short-term studies) or 1-4 mg/day (long-term studies). At Week 6, least squares mean differences (LSMDs, with 95% confidence limits [CLs]) for brexpiprazole (<i>n</i> = 868) vs placebo (<i>n</i> = 517) were: Positive symptoms: -1.55 (-2.30, -0.80), <i>P</i> < .0001, Cohen's <i>d</i> effect size (ES) = 0.27; Negative symptoms: -1.12 (-1.63, -0.61), <i>P</i> < .0001, ES = 0.29; Disorganized thought: -1.26 (-1.78, -0.74), <i>P</i> < .0001, ES = 0.32; Uncontrolled hostility/excitement: -0.76 (-1.15, -0.37), <i>P</i> = .0002, ES = 0.26; Anxiety/ depression: -0.56 (-0.91, -0.22), <i>P</i> = .0014, ES = 0.22. At last visit of the maintenance study, LSMDs (95% CLs) for brexpiprazole (<i>n</i> = 96) vs placebo (<i>n</i> = 104) were: Positive symptoms: -3.44 (-4.99, -1.89), <i>P</i> < .0001, ES = 0.62; Negative symptoms: -1.23 (-2.52, 0.07), <i>P</i> = .063, ES = 0.27; Disorganized thought: -1.69 (-2.81, -0.56), <i>P</i> = .0035, ES = 0.42; Uncontrolled hostility/excitement: -1.26 (-2.12, -0.39), <i>P</i> = .0046, ES = 0.41; Anxiety/depression: -0.72 (-1.47, 0.03), <i>P</i> = .061, ES = 0.27. In the OLEx studies, improvements were maintained over 58 (6 + 52) weeks of brexpiprazole treatment. In conclusion, these data suggest that brexpiprazole treats the continuum of schizophrenia symptoms, in the short- and long-term. Trial Registration: Data used in this <i>post hoc</i> analysis came from ClinicalTrials.gov identifiers: NCT01396421, NCT01393613, NCT01810380, NCT01668797, NCT01397786, NCT01810783.</p>","PeriodicalId":21348,"journal":{"name":"Schizophrenia Bulletin Open","volume":" ","pages":"sgab014"},"PeriodicalIF":0.0000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/schizbullopen/sgab014","citationCount":"2","resultStr":"{\"title\":\"Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: <i>Post Hoc</i> Analysis of Short- and Long-Term Studies.\",\"authors\":\"Stephen R Marder, Stine R Meehan, Catherine Weiss, Dalei Chen, Mary Hobart, Nanco Hefting\",\"doi\":\"10.1093/schizbullopen/sgab014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this <i>post hoc</i> analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) 'Marder factors.' Data were included from three 6-week, randomized, double-blind, placebo-controlled studies; a 52-week, randomized, double-blind, placebo-controlled maintenance treatment study; and two 52-week open-label extension (OLEx) studies-all in schizophrenia (DSM-IV-TR criteria). Patients receiving oral brexpiprazole were dosed at 2-4 mg/day (short-term studies) or 1-4 mg/day (long-term studies). At Week 6, least squares mean differences (LSMDs, with 95% confidence limits [CLs]) for brexpiprazole (<i>n</i> = 868) vs placebo (<i>n</i> = 517) were: Positive symptoms: -1.55 (-2.30, -0.80), <i>P</i> < .0001, Cohen's <i>d</i> effect size (ES) = 0.27; Negative symptoms: -1.12 (-1.63, -0.61), <i>P</i> < .0001, ES = 0.29; Disorganized thought: -1.26 (-1.78, -0.74), <i>P</i> < .0001, ES = 0.32; Uncontrolled hostility/excitement: -0.76 (-1.15, -0.37), <i>P</i> = .0002, ES = 0.26; Anxiety/ depression: -0.56 (-0.91, -0.22), <i>P</i> = .0014, ES = 0.22. At last visit of the maintenance study, LSMDs (95% CLs) for brexpiprazole (<i>n</i> = 96) vs placebo (<i>n</i> = 104) were: Positive symptoms: -3.44 (-4.99, -1.89), <i>P</i> < .0001, ES = 0.62; Negative symptoms: -1.23 (-2.52, 0.07), <i>P</i> = .063, ES = 0.27; Disorganized thought: -1.69 (-2.81, -0.56), <i>P</i> = .0035, ES = 0.42; Uncontrolled hostility/excitement: -1.26 (-2.12, -0.39), <i>P</i> = .0046, ES = 0.41; Anxiety/depression: -0.72 (-1.47, 0.03), <i>P</i> = .061, ES = 0.27. In the OLEx studies, improvements were maintained over 58 (6 + 52) weeks of brexpiprazole treatment. In conclusion, these data suggest that brexpiprazole treats the continuum of schizophrenia symptoms, in the short- and long-term. Trial Registration: Data used in this <i>post hoc</i> analysis came from ClinicalTrials.gov identifiers: NCT01396421, NCT01393613, NCT01810380, NCT01668797, NCT01397786, NCT01810783.</p>\",\"PeriodicalId\":21348,\"journal\":{\"name\":\"Schizophrenia Bulletin Open\",\"volume\":\" \",\"pages\":\"sgab014\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/schizbullopen/sgab014\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Schizophrenia Bulletin Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/schizbullopen/sgab014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Schizophrenia Bulletin Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/schizbullopen/sgab014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
摘要
精神分裂症的成功治疗需要一系列症状的改善。本事后分析的目的是表征布雷哌唑对阳性和阴性综合征量表(PANSS)的短期和长期影响。“马德尔因素。”数据来自三个为期6周的随机、双盲、安慰剂对照研究;一项52周、随机、双盲、安慰剂对照的维持治疗研究;以及两项为期52周的开放标签扩展(OLEx)研究——均为精神分裂症(DSM-IV-TR标准)。口服brexpiprazole的患者剂量为2-4 mg/天(短期研究)或1-4 mg/天(长期研究)。在第6周,布雷克斯哌唑(n = 868)与安慰剂(n = 517)的最小二乘平均差异(LSMDs, 95%置信限[CLs])为:阳性症状:-1.55 (-2.30,-0.80),P < 0.0001, Cohen's d效应大小(ES) = 0.27;阴性症状:-1.12 (-1.63,-0.61),P < 0.0001, ES = 0.29;无组织思维:-1.26 (-1.78,-0.74),P < 0.0001, ES = 0.32;失控的敌意/兴奋:-0.76 (-1.15,-0.37),P = 0.0002, ES = 0.26;焦虑/抑郁:-0.56 (-0.91,-0.22),P = 0.0014, ES = 0.22。在维持研究的最后一次访问时,brexpiprazole (n = 96) vs安慰剂(n = 104)的lsmd (95% CLs)为:阳性症状:-3.44 (-4.99,-1.89),P < 0.0001, ES = 0.62;阴性症状:-1.23 (-2.52,0.07),P = 0.063, ES = 0.27;无组织思维:-1.69 (-2.81,-0.56),P = 0.0035, ES = 0.42;失控的敌意/兴奋:-1.26 (-2.12,-0.39),P = 0.0046, ES = 0.41;焦虑/抑郁:-0.72 (-1.47,0.03),P = 0.061, ES = 0.27。在OLEx研究中,brexpiprazole治疗持续了58(6 + 52)周。总之,这些数据表明,布雷吡拉唑治疗精神分裂症症状的连续性,在短期和长期。试验注册:本事后分析使用的数据来自ClinicalTrials.gov识别码:NCT01396421、NCT01393613、NCT01810380、NCT01668797、NCT01397786、NCT01810783。
Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies.
The successful treatment of schizophrenia entails improvement across a spectrum of symptoms. The aim of this post hoc analysis was to characterize the short- and long-term effects of brexpiprazole on Positive and Negative Syndrome Scale (PANSS) 'Marder factors.' Data were included from three 6-week, randomized, double-blind, placebo-controlled studies; a 52-week, randomized, double-blind, placebo-controlled maintenance treatment study; and two 52-week open-label extension (OLEx) studies-all in schizophrenia (DSM-IV-TR criteria). Patients receiving oral brexpiprazole were dosed at 2-4 mg/day (short-term studies) or 1-4 mg/day (long-term studies). At Week 6, least squares mean differences (LSMDs, with 95% confidence limits [CLs]) for brexpiprazole (n = 868) vs placebo (n = 517) were: Positive symptoms: -1.55 (-2.30, -0.80), P < .0001, Cohen's d effect size (ES) = 0.27; Negative symptoms: -1.12 (-1.63, -0.61), P < .0001, ES = 0.29; Disorganized thought: -1.26 (-1.78, -0.74), P < .0001, ES = 0.32; Uncontrolled hostility/excitement: -0.76 (-1.15, -0.37), P = .0002, ES = 0.26; Anxiety/ depression: -0.56 (-0.91, -0.22), P = .0014, ES = 0.22. At last visit of the maintenance study, LSMDs (95% CLs) for brexpiprazole (n = 96) vs placebo (n = 104) were: Positive symptoms: -3.44 (-4.99, -1.89), P < .0001, ES = 0.62; Negative symptoms: -1.23 (-2.52, 0.07), P = .063, ES = 0.27; Disorganized thought: -1.69 (-2.81, -0.56), P = .0035, ES = 0.42; Uncontrolled hostility/excitement: -1.26 (-2.12, -0.39), P = .0046, ES = 0.41; Anxiety/depression: -0.72 (-1.47, 0.03), P = .061, ES = 0.27. In the OLEx studies, improvements were maintained over 58 (6 + 52) weeks of brexpiprazole treatment. In conclusion, these data suggest that brexpiprazole treats the continuum of schizophrenia symptoms, in the short- and long-term. Trial Registration: Data used in this post hoc analysis came from ClinicalTrials.gov identifiers: NCT01396421, NCT01393613, NCT01810380, NCT01668797, NCT01397786, NCT01810783.